Neurocrine Biosciences Inc (FRA:NB3)
€ 129.7 1.3 (1.01%) Market Cap: 12.97 Bil Enterprise Value: 12.33 Bil PE Ratio: 38.40 PB Ratio: 5.88 GF Score: 89/100

Neurocrine Biosciences Inc at Wells Fargo Healthcare Conference Transcript

Sep 07, 2023 / 07:45PM GMT
Release Date Price: €101.95 (-1.02%)
Mohit Bansal
Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst

Great. Thank you very much for joining us today. One more session to go after that. So we are close to being done. Thank you very much. My name is Mohit Bansal. I'm one of the biopharma analysts here at Wells Fargo, and I'm very happy to have Neurocrine management team with us. We have Kyle Gano, the Chief Business Development and Strategy Officer at Neurocrine. And we also have Todd Tushla, the Vice President at Investor Relations. Thank you, Kyle and Todd, for joining us today.

Kyle W. Gano
Neurocrine Biosciences, Inc. - Chief Business Development and Strategy Officer

Thank you.

Mohit Bansal
Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst

So maybe if you can -- before we get into Q&A, Kyle, if you can give a brief overview of what you are doing right now? And in terms of what is -- like when you talk to investors, what is on top of everyone's mind, so we can just frame the question today?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot